A Smart + Strong Site
Subscribe to:
POZ magazine

Back to home » Treatment News » Top Stories

Most Popular Stories
Undetectable Viral Load Essentially Eliminates Transmission Risk in Straight Couples
FDA Approves New Single-Tablet HIV Regimen, Triumeq
Life Expectancy for Young People With HIV Is Nearly Normal
A 15-Year Jump in Life Expectancy for People With HIV
Scientists Devise Method of Snipping HIV From Immune Cells
Monkey HIV Vaccine Success Opens Door for Human Trials
HIV Combo Pill Less Toxic Thanks to New Form of Tenofovir
What's That Mean?
(just double-click it!)

If you don't understand one of the words in this article, just double-click it. A window will open with a definition from mondofacto's On-line Medical Dictionary. If the double-click feature doesn't work in your browser, you can enter the word below:

Most Popular Lessons
Aging & HIV
The HIV Life Cycle
Herpes Simplex Virus
Syphilis & Neurosyphilis
Treatments for Opportunistic Infections (OIs)
What is AIDS & HIV?
More News

Have medical or treatment news about HIV? Send press releases, news tips and other announcements to news@aidsmeds.com.

Click here for more news


March 16, 2012

Treating HIV During Pregnancy Also Lowers Risk of Transmitting Hep C to Baby

by Tim Horn

CROI 2012 For women living with HIV and hepatitis C virus (HCV) coinfection, using HIV antiretroviral (ARV) therapy during pregnancy may lower the risk of transmitting both viruses to their infants, according to encouraging new data presented Tuesday, March 6, at the 19th Conference on Retroviruses and Opportunistic Infections (CROI) in Seattle.

Most research on mother-to-child transmission (MTCT) of hepatitis C was done before there was widespread access to combination ARV therapy among pregnant women living with HIV and HCV. In earlier years of the HIV pandemic, up to 19 percent of babies born to mothers living with HIV/HCV coinfection acquired HCV, versus 2 to 5 percent of babies born to mothers with HCV alone. Although combination ARV treatment has been proved to reduce MTCT of HIV, little has been known about the effects of modern-day HIV treatment combinations on MTCT of HCV.

Claudia Checa Cabot, MD, from the National Institute of Child Health and Human Development (NICHD) International Site Development Initiative (NISDI) and her international team of colleagues speculated that controlling HIV with ARV therapy in women living with HIV and hepatitis C might lower MTCT of both viruses.

Drawing from data collected from 2002 to 2008 in the Perinatal and Longitudinal Study in Latin American Countries (LILAC), Cabot and her colleagues reported that 739 of 1,409 pregnant HIV-positive women in the cohort had been tested for antibodies to HCV. Confirmatory testing for hepatitis C viral load (HCV RNA) was performed in all HCV antibody-positive women and women with a CD4 cell count of less than 200, even if the HCV antibody test result was negative.

Overall, 70 (9 percent) of the 739 women were HCV-antibody positive. Of this group, 44 (67 percent) had detectable hepatitis C virus (HCV RNA), as did an additional three women with low CD4 cell counts.

Mother-to-child transmission of HCV occurred in only four (8.5 percent) of the 47 infants born to women living with both viruses. None of the infants were born with HIV.

All of the mothers were taking ARV therapy while pregnant, and most had an HIV viral load of less than 1,000 copies when their babies were delivered.

All of the babies with hepatitis C were born to mothers with HCV RNA levels that were greater than 3.5 million copies during pregnancy. However, HCV RNA levels were not significantly lower among the mothers who did not transmit HCV to their infants.

Babies with detectable HCV RNA were considered to be living with hepatitis C. In one of the four infants, HCV RNA was less than 3,200 copies at 6 to 12 weeks after birth and became undetectable at 24 weeks.

“The HCV MTCT rate among HIV/HCV coinfected women with access to [combination ARV therapy] and well-controlled HIV infection may be lower than the transmission rates that were previously reported in other HIV/HCV coinfected populations, although our sample size and duration of study follow-up are limitations,” the researchers conclude. “Additional data from larger populations with longer infant follow-up are needed to better clarify whether populations of HIV-infected women with well-controlled HIV disease have lower HCV MTCT rates than what has been observed previously among HIV/HCV coinfected populations.”

Search: hiv, hepatitis c, hcv, transmission, mother to child, babies, infants, vertical, mtct, latin america, lilac, cabot, croi, seattle

Scroll down to comment on this story.


(will display; 2-50 characters)


(will NOT display)


(will display; optional)

Comment (500 characters left):

(Note: The AIDSmeds team reviews all comments before they are posted. Please do not include ":" "@" "<" ">" in your comment. The opinions expressed by people providing comments are theirs alone. They do not necessarily reflect the opinions of Smart + Strong, which is not responsible for the accuracy of any of the information supplied by people providing comments.)

Comments require captcha.
Please enter this number for verification:

| Posting Rules

Show comments (0 total)

[Go to top]

Quick Links
About HIV and AIDS
The Cure
Lab Tests
Clinical Trials
HIV Meds
Starting Treatment
Switching Treatment
Drug Resistance
Side Effects
Hepatitis & HIV
Women & Children
Fact Sheets
Treatment News
Community Forums
Conference Coverage
Health Services Directory
POZ Magazine
AIDSmeds on Twitter

Conference Coverage

XX International AIDS Conference
(AIDS 2014)
Melbourne, Australia
July 20 - 25, 2014

21st Conference on Retroviruses and Opportunistic Infections
(CROI 2014)
Boston, MA
March 3 - 7, 2014

7th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention
(IAS 2013)
Kuala Lumpur, Malaysia
June 30 - July 3, 2013

more conference coverage

[ about AIDSmeds | AIDSmeds advisory board | our staff | advertising policy | advertise/contact us]
© 2016 Smart + Strong. All Rights Reserved. Terms of use and Your privacy.
Smart + Strong® is a registered trademark of CDM Publishing, LLC.